newsfilter
← Latest News
ACCESS Newswire·

An Investigational Drug to Tackle Measles Outbreaks

NNVC
  • NanoViricides, Inc. (NYSE American: NNVC) is advancing its investigational broad-spectrum antiviral drug NV-387 toward clinical trials for Measles treatment.
  • The Company cites three recent child Measles deaths in the USA within ten days, alongside 5,164 confirmed cases across 47 jurisdictions as of November 5, 2026, with 4 confirmed fatalities.
  • NV-387 has completed Phase I human safety studies, Phase II trials for Ebola & Mpox in the DRC, juvenile animal model toxicity studies, & humanized mouse model efficacy studies against Measles.
  • Juvenile mouse studies determined a No Observed Adverse Effect Level (NOAEL) of 1,230 mg/kg per dose with no mortality or systemic toxicity, supporting potential clinical pediatric studies in infants as young as one month.
  • The Company plans to submit a Phase II protocol to the US FDA under an Investigational New Drug (IND) application, potentially utilizing the physician-initiated mechanism for severe cases.
  • NV-387 has received Rare Pediatric Disease Drug (RPDD) & Orphan Drug Designation (ODD) from the FDA for Measles treatment.
  • RPDD eligibility allows the Company to receive a Priority Review Voucher (PRV) upon successful marketing application, which can be sold to other pharmaceutical companies for up to $200 million.
  • Current Measles outbreaks in the USA & globally are driven by the D8 virus genotype, whereas existing vaccines are based on the A genotype, alongside rising vaccine hesitancy & breakthrough infections in vaccinated individuals.
  • Bangladesh reported 24,073 lab-confirmed cases & 105 fatalities between March 10 & November 10, 2026, despite aggressive vaccination campaigns.
  • NV-387 is described as a novel, host-mimetic nanomedicine that has demonstrated strong in vivo activity against Measles & other viral infections including RSV, COVID, Influenza, Mpox, & Smallpox.
  • The Company notes that vaccines do not treat infected patients, creating an unmet medical need for effective therapeutics to prevent severe outcomes like encephalitis & immune amnesia.
Company
NanoViricides
Keywords
Healthcare & Pharmaceutical, Company Update